title: Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer.
abstract: Neurensin-2 (NRSN2) is a 24KD protein, which is reported located in the membrane, while its biological functions remain unknown, not to mention in the field of tumor biology. In current study, we aimed to analyze the functions of NRSN2 in ovarian cancer. We screened TCGA database and surprisingly found that its copy number and mRNA level are gained and heightened respectively in parts of serous ovarian cancer patients. In current study, both loss- and gain- function assays found that NRSN2 is associated with the malignant phenotype in ovarian cancer cells, because NRSN2 plays a remarkable role in anchorage-independent colony formation, subcutaneous tumor formation, cell invasion, and chemoresistance. Furthermore, we found that the level of NRSN2 was positively correlated with the expression of stem cell marker CD133. In addition, Wnt canonical signaling and Twist/Akt/Erk axis were also regulated by NRSN2. In conclusion, we found that a poorly studied protein, NRSN2, which is associated with the malignant phenotype of serous ovarian cancer and as a membrane protein; it could be a target for serous ovarian cancer treatment.
authors.affiliation: The Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, China.
authors.forename: Wenbin
authors.initials: W
authors.lastname: Tang
authors.affiliation: The Department of Gynecology, Zhongshan Hospital Fudan University, China.
authors.forename: Aimin
authors.initials: A
authors.lastname: Ren
authors.affiliation: The Department of Gynecology, Zhongshan Hospital Fudan University, China.
authors.forename: Hongyang
authors.initials: H
authors.lastname: Xiao
authors.affiliation: The Department of Gynecology, Zhongshan Hospital Fudan University, China.
authors.forename: Huizhen
authors.initials: H
authors.lastname: Sun
authors.affiliation: The Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, China. Electronic address: binli_goghfu@sina.com.
authors.forename: Bin
authors.initials: B
authors.lastname: Li
mesh_terms: D000071916:AC133 Antigen / Q000378:metabolism; D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D000970:Antineoplastic Agents / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D005260:Female; D018628:Gene Dosage; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D009687:Nuclear Proteins / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D017239:Paclitaxel / Q000494:pharmacology; D010641:Phenotype; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D034622:RNA Interference; D015398:Signal Transduction; D014162:Transfection; D051879:Twist-Related Protein 1 / Q000378:metabolism; D015854:Up-Regulation
chemical_list: D000071916:AC133 Antigen; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D008565:Membrane Proteins; C546648:NRSN2 protein, human; D009687:Nuclear Proteins; C000606023:PROM1 protein, human; C103173:TWIST1 protein, human; D051879:Twist-Related Protein 1; D051057:Proto-Oncogene Proteins c-akt; D048049:Extracellular Signal-Regulated MAP Kinases; D017239:Paclitaxel; D002945:Cisplatin
keywords: Cancer cell stemness; Chemoresistance; Invasion; NRSN2; Ovarian cancer; Proliferation and growth